Literature DB >> 32641398

Reporting Considerations for Cefepime-Susceptible and -Susceptible-Dose Dependent Results for Carbapenemase-Producing Enterobacterales.

J A Fissel1, M L Yarbrough2, T Tekle1, C A Burnham2, P J Simner3.   

Abstract

Entities:  

Keywords:  Enterobacteraleszzm321990; Enterobacteriaceaezzm321990; antimicrobial susceptibility testing; breakpoints; carbapenemases; cefepime

Mesh：

Substances：

Year:  2020        PMID： 32641398      PMCID： PMC7448622          DOI： 10.1128/JCM.01271-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  11 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 2.  Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.

Authors:  Romney M Humphries; April N Abbott; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

3.  Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations.

Authors:  Jerry Altshuler; David J Guervil; Charles D Ericsson; Audrey Wanger; Samuel L Aitken; Luis Ostrosky-Zeichner
Journal:  J Pharm Pract       Date:  2017-03-06

4.  Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods.

Authors:  Renata C Picão; Ronald N Jones; Rodrigo E Mendes; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

5.  Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Authors:  Nathaniel J Rhodes; Joseph L Kuti; David P Nicolau; Scott Van Wart; Anthony M Nicasio; Jiajun Liu; Benjamin J Lee; Michael N Neely; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

6.  Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.

Authors:  A Gomez-Simmonds; B Nelson; D P Eiras; A Loo; S G Jenkins; S Whittier; D P Calfee; M J Satlin; C J Kubin; E Y Furuya
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  Breakpoint beware: reliance on historical breakpoints for Enterobacteriaceae leads to discrepancies in interpretation of susceptibility testing for carbapenems and cephalosporins and gaps in detection of carbapenem-resistant organisms.

Authors:  Melanie L Yarbrough; Meghan A Wallace; Robert F Potter; Alaric W D'Souza; Gautam Dantas; Carey-Ann D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-02       Impact factor: 3.267

Review 8.  Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.

Authors:  Joshua T Thaden; Jason M Pogue; Keith S Kaye
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

Review 9.  Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Haley J Morrill; Jason M Pogue; Keith S Kaye; Kerry L LaPlante
Journal:  Open Forum Infect Dis       Date:  2015-05-05       Impact factor: 3.835

10.  Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Authors:  Yohei Doi
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.